Navigation Links
Orexigen in Medical News

Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results

...Months Ended June 30, 2009 As of June 30, 2009, orexigen held $8.6 million in cash and cash equivalents and...ent securities, available-for-sale. In July 2009, orexigen completed a public offering, the estimated net pro... For the three months ended June 30, 2009, orexigen reported a net loss of $17.8 million, or $0.51 per...

Orexigen(R) Therapeutics Prices Public Offering of Common Stock

... SAN DIEGO, July 23 /PRNewswire-FirstCall/ -- orexigen Therapeutics, Inc. (Nasdaq: OREX ) today announc...ted expenses, will be approximately $70.9 million. orexigen has granted the underwriter a 30-day option to pur...he securities described above are being offered by orexigen pursuant to a registration statement previously fi...

Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock

... SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- orexigen Therapeutics, Inc. (Nasdaq: OREX ) today announc...public offering. In connection with this offering, orexigen expects to grant to the underwriter a 30-day optio...he securities described above are being offered by orexigen pursuant to a registration statement previously fi...

-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-

...k and slow down the weight loss process. orexigen reported the results of the COR-BMOD (NB-302) tria...bo. About Orexigen(R) Therapeutics orexigen Therapeutics, Inc. is a biopharmaceutical company ....com. Forward-Looking Statements orexigen cautions you that statements included in this pres...

Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)

...el Narachi, President and Chief Executive Officer, orexigen Therapeutics. In exchange for undisclosed upfront and future milestone payments, orexigen secured non-exclusive rights to certain formulatio...f 2010. About Orexigen(R) Therapeutics orexigen Therapeutics, Inc. is a biopharmaceutical company ...

Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer

...inical development. "I'm thrilled to join the orexigen team and to have the opportunity to impact the tre...cant unmet need," said Narachi. "I believe in the orexigen opportunity and, in particular, in the potential o...niversity of California, Los Angeles . About orexigen Therapeutics ...

Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors

...fy received a B.A. from Lewis and Clark College and an M.A. from Columbia School of International Affairs. About Orexigen(R) Therapeutics orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for...

Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference

...gs.com/webcasts/jpmorgan/healthcare09/directlink?ticker=OREX About orexigen Therapeutics orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment ...

Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008

.... On November 6, 2008 at 5:00 p.m. Eastern time, orexigen management will host the call and webcast to discu...ew York November 18, 2008 11:25 a.m. EST About orexigen Therapeutics orexigen Therapeutics, Inc. is a biopharmaceutical company ...

Catalyst Biosciences Appoints Dr. Todd Lorenz Chief Medical Officer

...entities including Scios, the Corporate Office of Science and Technology and Peninsula Pharmaceuticals. Dr. Lorenz served as Chief Medical Officer for orexigen Therapeutics from 2005-2006 and was Chief Medical Officer at Corgentech from 2001-2005 where he was responsible for the clinical development of a tran...
Orexigen in Medical Technology

Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results

...nference call at 8:00 a.m. Eastern time. orexigen management will host the call and webcast to discu...ssed live on the investor relations section of the orexigen web site at www.orexigen.com , and will be arch... for 14 days following the call. About orexigen Therapeutics ...

Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team

...previously disclosed diagnosis of acute leukemia. orexigen has retained an executive search firm to assist it...nical trial for Contrave in January. About orexigen Therapeutics orexigen Therapeutics, Inc. is a biopharmaceutical company ...

Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)

...ials - PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- orexigen Therapeutics, Inc. (Nasdaq: OREX ), a biopharmace... adverse event. About Orexigen(R) Therapeutics orexigen Therapeutics, Inc. is a biopharmaceutical company ...ression and sustained weight loss. Beyond obesity, orexigen is developing drug combinations for use in schizop...

Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule

... orexigen is the only company with two late-stage product ca...II development," said Gary Tollefson, M.D., Ph.D., orexigen President and CEO. "Empatic continues to be an imp...omplementary segment within the obesity market." orexigen is the only company currently developing two late-...

OREXIGEN Therapeutics Announces Sustained-Release Formulation of Zonisamide Shows Improved Tolerability When Compared to Immediate Release Formulation

...ident and CEO. About Orexigen(TM) Therapeutics orexigen Therapeutics, Inc. is a biopharmaceutical company .../www.orexigen.com . Forward-Looking Statements orexigen cautions you that statements included in this pres...es relating to the central nervous system on which orexigen has based its development programs may not result ...

Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23

...n obese subjects with Type II diabetes. About orexigen Therapeutics Orexigen(TM) Therapeutics, Inc. is .../www.Orexigen.com . Forward Looking Statements orexigen cautions you that statements included in this pres...uld result in recalls or product liability claims; orexigen and its licensors may not be able to obtain, maint...
Orexigen in Biological News

OHSU turns innovations into commercial opportunities at record pace

...et value of equity OHSU owns in six startups whose shares are publicly traded Novacea, Inc.; Adherex Technologies Inc.; Neurocrine Biosciences, Inc.; orexigen Therapeutics, Inc.; StemCells, Inc. and Fonix Corporation reached $2.25 million at the end of the fiscal year, up from $1.5 million the previous year...
Orexigen in Biological Technology

Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference

...Room Speaker: Michael Narachi, Chief Executive Officer About orexigen Therapeutics orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the developmen...

Biotech Hot in July Driven by Positive Drug Data and Acquisitions

...n measurement, as well as reducing depression, irritability and severity of illness, and leading to better cognition and overall improvement. - orexigen Therapeutics shares jumped 54 percent in July after revealing that Contrave, a longer lasting form of two generic diet drug compounds, helped people l...

Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters

... SAN DIEGO, July 24 /PRNewswire-FirstCall/ -- orexigen Therapeutics, Inc. (Nasdaq: OREX ) today announc...he securities described above are being offered by orexigen pursuant to a registration statement previously fi...14. About Orexigen(R) Therapeutics orexigen Therapeutics, Inc. is a biopharmaceutical company ...

Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions

...," said Eduardo Dunayevich, Chief Medical Officer, orexigen Therapeutics. "Furthermore, due to its unique eff...el Narachi, President and Chief Executive Officer, orexigen Therapeutics. "These data, which we believe meet ...ocess. About Orexigen(R) Therapeutics orexigen Therapeutics, Inc. is a biopharmaceutical company ...

2009 Pharma ChemOutsourcing Show Attendance Up an Astounding 60% Despite Current Recession

...tional speakers include BioMarin Pharmaceuticals, Array BioPharma, Reata Pharmaceuticals, Proteolix, Novalar Pharmaceuticals, Lexicon Pharmaceuticals, orexigen Therapeutics, Targacept, Helsinn Therapeutics, OSI Prosidion, NovaDel Pharma, Anacor Pharmaceuticals, Ceragenix, Millennium Pharmaceuticals (Takeda), ...

Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings

...r 56 Weeks" Time: 11:15 a.m. ET Location: Room 152AB About orexigen Therapeutics orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment ...

Orexigen(R) Therapeutics to Present at Upcoming Meetings

...ancisco Speaker: Graham Cooper, Chief Financial Officer About orexigen Therapeutics orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment ...

Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy

... add someone of Jay's breadth of experience to the orexigen executive team, " said Michael Narachi, President ...lopment. "I'm incredibly excited to join the orexigen team at this pivotal time for the Company," said J...University of California, San Diego . About orexigen Therapeutics ...

Orexigen(R) Therapeutics to Speak at Upcoming Conferences

... York Speaker: Graham Cooper, Chief Financial Officer About orexigen Therapeutics orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment ...

Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results

...nths Ended March 31, 2009 As of March 31, 2009, orexigen held $19.8 million in cash and cash equivalents an... For the three months ended March 31, 2009, orexigen reported a net loss of $19.3 million, or $0.56 per...et that Contrave may address. orexigen is continuing to follow patients in a Phase 2b cli...
Orexigen in Biological Dictionary

Affymetrix

...x Incorporated's latest news headlines at MainStreet.com Research AFFYMETRIX INC historical prices, historical volume, splits and dividends. ... orexigen Therapeutics, Repligen and Affymetrix lead small-cap volume in ... Affymetrix to Host Conference Call on July 22, 2009 to Announce Second Quart...
Other Tags
(Date:8/3/2015)... ... August 03, 2015 , ... A recent survey ... number of Hispanics believe people can positively affect their diabetes, few look beyond ... said making diet changes was important. Far fewer participants mentioned the need for ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today ... management solution, as well as announced the date of its next major release. ... of contract management tasks as well as enhancements to the customer experience. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... to Ahjumawi Lava Springs, California’s northernmost and among its least visited State Parks. ... water aquifers, whose main outflow is at Ahjumawi Lava Springs, part of the ...
(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science (IHS) has completed ... The acquisition includes all of IBAM NA’s cyclotron sites and research and development facilities. ... regionally located business, as well as a large manufacturing hub in Noblesville, Indiana,” said ...
(Date:8/3/2015)... Spring, MD (PRWEB) , ... August 03, 2015 , ... ... the addition of a new associate podiatrist, creating the largest medical practice in the ... foot and ankle medicine. FASMA operates 21 locations with 33 doctors. , Dr. Hetal ...
Breaking Medicine News(10 mins):Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Novatus Unveils Milestone Software Release 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
Other Contents